CC Diagnostics recognises the preventability of cervical cancer in women
Cervical cancer is a worldwide problem, but with regular and decent screening it is mostly preventable since with regular screening, the early precancerous changes in cervical cells can be detected and treated. We have the goal to improve this screening by making it more accurate and easier for women to participate.
Novel methylation test kit for the epigenetic detection of early stage cervical cancer
We are going to do this by implementing a new diagnostic test aiming at methylated genes, making use of PCR-technology. This test will replace the current triage test, the PAP-test. The methylation test is more accurate, bringing missed cancer cases from 24% to 3%, and reducing false-positives which would save €2.9M in yearly healthcare costs in the Netherlands alone.
Development
For the development of the test kit, CC Diagnostics works in cooperation with partners specialised in technical kit development, assay validation, clinical trials and performing pilot tests.
Management
The management team of CC Diagnostics consists of Ronald Vos (CEO) and Nutte van Belzen (CMO).
Recent news
CC Diagnostics laatste finalist YBA
Dagblad van het Noorden 27 mei 2017 zaterdag - Editie Noord-Drenthe CC Diagnostics laatste finalist YBA SECTION: ECONOMIE; Blz. 36LENGTH: 73 woorden EMMEN De Groningse startup CC Diagnostics heeft zichzelf als laatste geplaatst voor de finale van de Young Business...